A comparison of two Fendrix hepatitis B vaccination schedules in patients with inflammatory bowel disease
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved..
Systemic immunosuppressive therapy (IS) renders patients with inflammatory bowel disease (IBD) vulnerable to fulminant hepatitis B virus (HBV) infection. Seroprotection against HBV through a full vaccination scheme is preferably obtained before IS is initiated, but often conflicts with the clinical need to initiate therapy rapidly. Consequently, the vast majority of patients will use IS during booster vaccinations. In this retrospective cohort study, we examined the serological response after a modified vaccination schedule which includes an initial double dose of Fendrix in patients with IBD and compared the results with the serological responses of patients with IBD who received the standard schedule. Seroprotection rates were 86.2 % and 88.9 % in the modified and standard schedule groups respectively. One-third of patients obtained seroprotection after only one double dose vaccine. A double dose may be considered in patients with IBD at high short-term risk of HBV infection when a rapid protective response is warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Vaccine - 40(2022), 43 vom: 12. Okt., Seite 6201-6205 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kuiper, Vincent P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fendrix |
|---|
| Anmerkungen: |
Date Completed 11.10.2022 Date Revised 30.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2022.09.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346710170 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346710170 | ||
| 003 | DE-627 | ||
| 005 | 20231226032114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2022.09.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM346710170 | ||
| 035 | |a (NLM)36154758 | ||
| 035 | |a (PII)S0264-410X(22)01100-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kuiper, Vincent P |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A comparison of two Fendrix hepatitis B vaccination schedules in patients with inflammatory bowel disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.10.2022 | ||
| 500 | |a Date Revised 30.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Systemic immunosuppressive therapy (IS) renders patients with inflammatory bowel disease (IBD) vulnerable to fulminant hepatitis B virus (HBV) infection. Seroprotection against HBV through a full vaccination scheme is preferably obtained before IS is initiated, but often conflicts with the clinical need to initiate therapy rapidly. Consequently, the vast majority of patients will use IS during booster vaccinations. In this retrospective cohort study, we examined the serological response after a modified vaccination schedule which includes an initial double dose of Fendrix in patients with IBD and compared the results with the serological responses of patients with IBD who received the standard schedule. Seroprotection rates were 86.2 % and 88.9 % in the modified and standard schedule groups respectively. One-third of patients obtained seroprotection after only one double dose vaccine. A double dose may be considered in patients with IBD at high short-term risk of HBV infection when a rapid protective response is warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Fendrix | |
| 650 | 4 | |a Hepatitis B | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Vaccination | |
| 650 | 7 | |a Fendrix |2 NLM | |
| 650 | 7 | |a Hepatitis B Antibodies |2 NLM | |
| 650 | 7 | |a Hepatitis B Vaccines |2 NLM | |
| 700 | 1 | |a van der Plas, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Hoogerwerf, Marie-Astrid |e verfasserin |4 aut | |
| 700 | 1 | |a Pieter R Koopman, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a van der Meulen, Andrea E |e verfasserin |4 aut | |
| 700 | 1 | |a Roukens, Anna H E |e verfasserin |4 aut | |
| 700 | 1 | |a Visser, Leo G |e verfasserin |4 aut | |
| 700 | 1 | |a Roestenberg, Meta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 40(2022), 43 vom: 12. Okt., Seite 6201-6205 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:43 |g day:12 |g month:10 |g pages:6201-6205 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2022.09.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 43 |b 12 |c 10 |h 6201-6205 | ||